Director at Ningbo No. 2 Hospital, China
Dr. Hongshan Li, a distinguished expert in Traditional Chinese Medicine, serves as the Chief Physician and Director of the Liver Disease Department at Ningbo No. 2 Hospital. With a doctorate from Shanghai University of Traditional Chinese Medicine, he specializes in liver diseases. Dr. Li has led significant research projects funded by the National Natural Science Foundation of China and has been honored with multiple awards for his contributions to integrative medicine. He is also a doctoral supervisor and a prominent figure in Zhejiang Province’s medical community, recognized for his innovative approaches and leadership in liver disease diagnosis and treatment. Macromolecules
Professional Profiles
Education
Doctor of Internal Medicine of Traditional Chinese Medicine (Liver Disease) Institution: Shanghai University of Traditional Chinese Medicine Duration: September 2017 – June 2020 Master of Internal Medicine of Traditional Chinese Medicine (Liver Disease) Institution: Shanghai University of Traditional Chinese Medicine Duration: September 2005 – June 2008 Bachelor of Traditional Chinese Medicine Institution: Henan University of Chinese Medicine Duration: September 2000 – June 2005 Macromolecules
Professional Experience
Chief Physician of Traditional Chinese Medicine, Department Director Institution: Liver Disease Department of Integrative Medicine, Ningbo No. 2 Hospital Duration: January 2022 – Present Subject Leader, Department Director Institution: Liver Disease Department of Integrative Medicine, Ningbo No. 2 Hospital Duration: May 2020 – December 2021 Associate Director of Traditional Chinese Medicine Institution: Liver Disease Department of Integrative Medicine, Ningbo No. 2 Hospital Duration: January 2017 – April 2020 Traditional Chinese Medicine Physician, Attending Traditional Chinese Medicine Physician Institution: Liver Disease Department of Integrative Medicine, Ningbo No. 2 Hospital Duration: July 2008 – December 2016
Scientific Research Projects
National Natural Science Foundation of China (General Projects) Project: Study on the effect mechanism of HJJB formula in regulating hepatic lipid metabolism in NAFLD based on nuclear receptor FXR National Natural Science Foundation of China Youth Science Foundation Project Project: Study on the mechanism of the ‘HJJB’ compound in the prevention and treatment of NAFLD based on insulin signal transduction Zhejiang Natural Science Foundation Project Project: Study on the mechanism and main effect components of ‘HJJB’ compound in improving liver fat metabolism in NAFLD National Administration Of Traditional Chinese Medicine-Zhejiang Province Co-Construction Science and Technology Program Key Projects Project: Clinical efficacy evaluation and mechanism study of QTHX compound in the treatment of metabolic-related fatty liver disease Macromolecules
Titles and Honors
Doctoral Supervisor, Ningbo University Leading Medical and Health Talents, Zhejiang Province Chinese Medicine Innovation Team Leader, Zhejiang Province Key Laboratory Leader, Zhejiang Provincial Key Laboratory of Diagnosis, Treatment and Research of Digestive System Tumors High-Level Health Talent, Zhejiang Province Medical New Talent, Third Phase, Zhejiang Province Yongjiang Talent Project Leader and Top Talent First-Level Cultivation Object Ningbo Medical Key Discipline Leader (Integrative Medicine) Ningbo Youth Science and Technology Award Winner Ningbo Leading Talent Macromolecules
Publications
- Geniposide plus chlorogenic acid reverses non-alcoholic steatohepatitis via regulation of gut microbiota and bile acid signaling in a mouse model in vivo, Publication date: 2023.
- Glial cell line-derived neurotrophic factor (GDNF) mediates hepatic stellate cell activation via ALK5/Smad signalling, Publication date: 2019.
- Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease, Publication date: 2020.
- Efficacy and Mechanism of a Chinese Classic Prescription of Yueju in Treating Nonalcoholic Steatohepatitis and Protecting Hepatocytes from Apoptosis, Publication date: 2020.
- Salidroside improves high-fat diet-induced non-alcoholic steatohepatitis by regulating the gut microbiota–bile acid–farnesoid X receptor axis, Publication date: 2020.
- Gypenosides ameliorate high-fat diet-induced non-alcoholic steatohepatitis via farnesoid X receptor activation, Publication date: 2022.
- Intestinal Microecology: An Important Target for Chinese Medicine Treatment of Non-alcoholic Fatty Liver Disease, Publication date: 2020.
- Gypenosides ameliorate high-fat diet-induced non-alcoholic steatohepatitis via farnesoid X receptor activation, Publication date: 2022.
.